Athira Pharma presents initial results from phase 1 trial of NDX-1017
Category: #health  By Mateen Dalal  Date: 2019-07-18
  • share
  • Twitter
  • Facebook
  • LinkedIn

Athira Pharma presents initial results from phase 1 trial of NDX-1017

The company has been looking forward to initiate larger phase 2 trials.

The clinical-stage company Athira Pharma, Inc. has reportedly announced preliminary data from the phase 1 clinical trial of its lead therapeutic molecule, NDX-1017, at the Alzheimer’s Association International Conference 2019 (AAIC) in Los Angeles, California. 

Apparently, the randomized double-blind, placebo-controlled trial has been evaluating NDX-1017 in various trial cohorts. Outcomes from the phase 1a and 1b segments of the trial in 72 healthy young and elderly individuals has shown that NDX-1017 is well-tolerated and safe at various dose levels.

Additionally, a potent pharmacodynamic biomarker signal was detected in study participants receiving NDX-1017, representing its ability to penetrate through the blood brain barrier and efficiently engaging with its target across a range of doses. This was demonstrated by dose-dependent upsurges in electroencephalogram (EEG) signals, which have been proved to be related with memory and learning.

Leen Kawas, CEO, Athira, reportedly stated that the organization has been inspired by the outcomes and has accomplished all primary goals from the phase 1 trial in these first cohorts. The company has noted that NDX-1017 successfully overcomes the blood brain barrier and evidently effects the brain as observed through EEG as a biomarker, he further stated.

According to reliable sources, complete outcomes from the trial, including assessment in individuals enduring Alzheimer’s disease or slight cognitive impairment, will be declared later this year. Athira has been looking forward to initiate larger phase 2 trials.

For the record, Athira is a drug development firm determined to enhance human health by developing new therapies for neurodegenerative diseases like Alzheimer’s and Parkinson’s. The company is headquartered in Seattle, Washington. It is presently developing its key therapeutic candidate NDX-1017 which is an innovative small molecule therapy designed to slow, halt or reverse the effects of Alzheimer’s and other neurodegenerative diseases instead of only alleviating disease symptoms. 

Source credit: https://athira.com/athira-pharma-presents-preliminary-results-from-phase-1-trial-of-ndx-1017-at-alzheimers-association-international-conference-2019-aaic/

https://www.biospace.com/article/releases/athira-pharma-presents-preliminary-results-from-phase-1-trial-of-ndx-1017-at-alzheimer-s-association-international-conference-2019-aaic-/

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

Delta and Virgin Atlantic to expand transatlantic services by 2020
Delta and Virgin Atlantic to expand transatlantic services by 2020
By Mateen Dalal

This will be the first time that both the carriers will be serving Gatwick airport since their partnership in 2014 British airlines Virgin Atlantic and the American airline Delta recently announced increased services between the US and UK by the yea...

Ola acquires AI firm Pikup.ai to further enhance its deep tech skills
Ola acquires AI firm Pikup.ai to further enhance its deep tech skills
By Mateen Dalal

Startup Pikup.ai utilizes automated technologies like sensor fusion, computer vision, and Artificial Intelligence to offer AI-based solutions for businesses.   Ola is increasing company’s aim on utilizing deep technology and advanced a...

Sonnet to acquire Relief Therapeutics to develop atexakin alfa
Sonnet to acquire Relief Therapeutics to develop atexakin alfa
By Mateen Dalal

Sonnet proposes to pay 7,111,947 common shares and outstanding common stocks to Relief Therapeutics. Sonnet BioTherapeutics, Inc., a biotechnology company that develops innovative biologic drugs, has recently announced that it has entered into an ag...